A Study to Investigate the Effects of Durvalumab with Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

Trial Identifier: AZ-RU-00003
Sponsor: AstraZeneca
Start Date: September 2024
Primary Completion Date: June 2026
Study Completion Date: June 2027
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
RU Ekaterinburg, RU, 620905
RU Kazan, RU, 420029
RU Moscow, RU, 111123
RU Moscow, RU, 115478
RU MOSCOW, RU, 143423
RU Nizhny Novgorod, RU, 603126
RU Novosibirsk, RU, 630108
RU Obninsk, RU, 249031
RU St. Petersburg, RU, 197758
RU St.Petersburg, RU, 197022
RU Ufa, RU, 450054